Adebrelimab or placebo plus carboplatin and etoposide as first-line treatment for extensive-stage small-cell lung cancer (CAPSTONE-1): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial
Resource Type
Article
Authors
Cheng, Ying ; Wang, Jie ; Zhou, Caicun ; Yao, Wenxiu ; Wang, Qiming ; Min, Xuhong ; Chen, Gongyan ; Xu, Xingxiang ; Li, Xingya ; Xu, Fei ; Fang, Yong ; Yang, Runxiang ; Yu, Guohua ; Gong, Youling ; Zhao, Jun ; Fan, Yun ; Liu, Quan ; Cao, Lejie ; Yao, Yu ; Liu, Yunpeng ; Li, Xiaoling ; Wu, Jingxun ; He, Zhiyong ; Lu, Kaihua ; Jiang, Liyan ; Hu, Chengping ; Zhao, Wenhua ; Yu, Huiqing ; Zhao, Jian ; Wu, Gang ; Huang, Dingzhi ; Chen, Chengshui ; Ding, Cuimin ; Zhang, Baihong ; Wang, Xiuwen ; Luo, Hui ; Li, Baolan ; Zhang, Shucai ; Lu, Hong ; Shi, Meiqi ; Chen, Xi ; Guo, Yubiao ; Liu, Hailong ; Liu, Jiwei ; Gao, Hongjun ; Hu, Sheng ; Hong, Qunying ; Li, Qi ; Zhang, Ben ; Shi, Wei ; Zhang, Xiaojing
Source
In The Lancet Oncology June 2022 23(6):739-747
Subject
Primary Research Articles
Language
ISSN
1470-2045